Conclusions: Due to the role of B-Myb and E2F1 transcription factors in controlling cell cycle progression of leukemic cells, the down-regulation of these oncogenes by miR-34a suggests the usefulness of therapeutic approaches aimed to modulate the levels of miR-34a.
Introduction
Nutlin-3a represents a potent and selective small molecule inhibitor of the p53-MDM2 interaction (1) , which raises the levels of p53 protein and induces subsequent cytostatic or cytotoxic effects in a variety of tumor cells (1) . Taking into consideration that p53 is mutated in less than 15% of hematological malignancies at diagnosis (2) , it is noteworthy that Nutlin-3 has shown in vitro promising therapeutic potential in both myeloid and lymphoid leukemia characterized by a p53 wildtype status (3) (4) (5) (6) (7) (8) (9) . However, since p53 mediates different cellular functions, such as in particular cell cycle arrest and apoptosis (3) the critical molecular determinants mediating/modulating the therapeutic activity of Nutlin-3 in leukemic cells are incompletely understood.
Previous studies have shown that several solid tumors are characterized by overexpression of B-Myb, also known as MYBL2 (10) (11) (12) (13) , a member of the vertebrate MYB family of nuclear transcription factors, which recognize and bind to the DNA consensus sequence (PyAAC(G/T)G) to promote gene transcription (14) . B-Myb, unlike C-Myb and A-Myb, is expressed in virtually all proliferating cells as a regulator of cell cycle progression and cell survival (15) and it plays an essential role in vertebrate development (16). Indeed, knocking-down murine B-Myb causes early embryonic lethality (E4.5-6.5) resulting from unsuccessful inner cell mass formation (16).
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Western blot analyses
Cells were lysed in ice-cold Ripa buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.1% SDS, 1% Nonidet P-40, 0.25% sodium desoxycholate) supplemented with protease inhibitors (Complete, Roche; Mannheim, Germany) on ice for 1 hour. Protein determination was performed by BCA Protein Assay (Thermo Scientific, Rockford, IL) and then additioned with loading buffer (250 mM Tris pH 6.8, 2% SDS, 40% Glycerin, 20% beta-mercaptoethanol) and boiled for 2 min (22) . Equal amounts of protein for each sample were migrated in acrylamide gels and blotted onto nitrocellulose filters, as previously described. The following mAb were used in our experiments: anti p53 (DO- 
Transfection experiments
Cells (1x10 6 ) were resuspended into 0.1 ml of Nucleofector TM solution of human nucleofector
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8 In miR-34a functional studies, cells were transfected with the hsa-miR-34a precursor oligo, for mimicking the overexpression of this miRNA, or with the hsa-miR-34a anti-miR oligo, for the inhibition of the activity of endogenous miR-34a. In parallel, cells were transfected with the FAMlabeled miR negative control oligo as a nontargeting negative control and for monitoring transfection efficiency. All oligos were from Ambion. Figure 1) . AML samples showed significantly (p<0.01) greater levels of B-Myb mRNA as compared to normal CD34 + cells (Supplementary Figure 1) . Also B-CLL showed an increase of B-Myb mRNA endogenous levels with respect to primary CD19 + B cells but the difference did not reach statistically significance.
Statistical analysis
Since a constitutive expression of B-Myb can bypass p53-mediated G1 arrest and is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells (24) Since it has been demonstrated that B-Myb is a transcriptional target of E2F1 (25, 26) and previous studies have shown that E2F1 is down-modulated by Nutlin-3 in solid tumor models (27) in parallel, we have analyzed the effect of Nutlin-3 on E2F1 expression. As shown in Figure 1C , treatment with Nutlin-3 strikingly down-regulated also E2F1 RNA levels in the p53 and endothelial cells (Figure 3B ), but with negligible effects on the background levels of apoptosis (data not shown). Taken together, these findings suggested that the transcription down-regulation of B-Myb by Nutlin-3 was related to its ability to block cell cycle, rather than to its ability to induce apoptosis. To further elucidate the potential cause-effect relationship between down modulation of B-Myb and cell cycle arrest, we have performed knockdown experiments of endogenous B-Myb by using fibroblast cultures, which were used for their high efficiency of transfection. As shown in Figure 3C , at 24-48 hours after B-Myb siRNA transfection we observed a marked, and specific, decrease of B-Myb mRNA, but not of p53 (analyzed for control; data not shown), accompanied by a significant (p<0.01) decrease of the percentage of cell in S-phase ( Figure 3C ).
Key role of miR-34a in mediating the down-regulation of B-Myb by Nutlin-3
To characterize the mechanism of B-Myb transcription repression by Nutlin-3, we have Figure 1B-D) . As shown in Figure 4B , we have observed a significant induction of miR-34a in response to Nutlin-3 treatment in all p53
wild-type CCR-10-3244.R1 miR-34a. Thus, to functionally test the hypothesis that miR-34a decreases B-Myb expression, we transfected primary fibroblasts with the precursor to miR-34a (designated miR-34a mimic). As a control, some cells were transfected with scrambled miRNA. As shown in Figure 5A , the precursor to miR-34a significantly (p<0.01) decreased B-Myb levels. Consistently with previous studies (34, 35) overexpression of miR-34a also down-modulated E2F1 expression (Figure 5B) . On the other hand, it did not affect p53 and p21 expression ( Figure 5B) . In additional experiments, the downregulation of miR34a with a specific antago-miR significantly (p<0.05) counteracted the ability of Nutlin-3 of down-regulating both E2F1 and B-Myb ( Figure 5C ). In this respect, it has been recently reported that miRNA-34a, regulated by C/EBPa during granulopoiesis, modulates directly E2F3 and indirectly E2F1, a major transcriptional target of
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p53 wild-type leukemic cells, suggesting that it might display superior therapeutic efficacy as compared to commonly used chemotherapeutic drugs. The ability of miR34a to down-regulate B-Myb was clearly related to cell cycle arrest rather than apoptosis induction in both malignant cells and primary normal fibroblasts and endothelial cells, suggesting that therapeutic approaches able to raise the levels of miR34a will likely results in anti-angiogenic activity.
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